| 0.9245 0.025 (2.79%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.25 | 1-year : | 1.43 |
| Resists | First : | 1.07 | Second : | 1.23 |
| Pivot price | 0.96  |
|||
| Supports | First : | 0.82 | Second : | 0.68 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.97 |
| MA(100) : | 1.28 |
MA(250) : | 2.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.6 |
D(3) : | 25.5 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 4.07 | Low : | 0.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKBA ] has closed above bottom band by 29.4%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.96 | 0.96 - 0.97 |
| Low: | 0.87 - 0.88 | 0.88 - 0.88 |
| Close: | 0.92 - 0.92 | 0.92 - 0.93 |
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Wed, 10 Jun 2026
Only U.S. oral HIF-PH anemia drug secures patents into 2030s - Stock Titan
Mon, 01 Jun 2026
New Akebia hire receives 8,400 stock options at $1.02 - Stock Titan
Mon, 01 Jun 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Thu, 28 May 2026
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewswire
Thu, 28 May 2026
Kidney disease-focused Akebia to present at NY healthcare conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 268 (M) |
| Shares Float | 262 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 26,370 (K) |
| Shares Short P.Month | 27,310 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | -8.9 % |
| Operating Margin | -2.8 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | -79 % |
| Qtrly Rev. Growth | -6.6 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 0.86 |
| EBITDA (p.s.) | 0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 60 (M) |
| Levered Free Cash Flow | 66 (M) |
| PE Ratio | -11.56 |
| PEG Ratio | 0 |
| Price to Book value | 9.24 |
| Price to Sales | 1.06 |
| Price to Cash Flow | 4.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|